stockrow
Saturday 7 November 2026
Export HCWB’s income statement to Excel — free account
HCW Biologics Inc.
HCWB Healthcare Biotechnology
HCW Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54,200.00, down 97.9% from fiscal 2024.
- Revenue
- +1,954.6%
- EPS
- +71.6%
- Free cash flow
- −20.8%
- Total debt
- −3.34%
Quarter to June 2026, against a year earlier
1.02
0.02
−1.92%
Follow HCWB
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.99 | 0.30 | 37.48 | 19.81 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.67) | (1.24) | (0.61) | (2.58) | |
P/B ratio |
0.89 | 0.34 | 0.74 | 0.00 | |
Price to Tangible BV |
0.89 | 0.34 | 0.74 | 0.00 | |
EV/Sales |
1.91 | 1.16 | 133.69 | 34.21 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.06) | (0.67) | (0.54) | (1.12) | |
EV/FCF |
(1.03) | (0.65) | (0.53) | (1.10) | |
Quick Ratio |
0.04 | 0.07 | 0.09 | 0.04 | |
Current Ratio |
0.06 | 0.09 | 0.11 | 0.06 | |
Net Debt/EBITDA |
(1.91) | 1.58 | (1.13) | (1.83) | |
Debt/Assets |
24.51% | 24.06% | 27.77% | 26.75% | |
Debt/Equity |
0.88 | 1.14 | 2.46 | (3.23) | |
Asset Turnover |
0.24 | 0.25 | 0.00 | 0.02 | |
Operating CF/Net income |
0.26 | (1.25) | 0.97 | 0.71 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(31.51) | 29.60 | (19.03) | (25.90) | |
Research and Development Expense of Revenue |
887.46% | 19.23% | 4,937.41% | 9,001.28% | |
Selling, General and Administrative Expense of Revenue |
1,379.35% | 28.02% | 5,528.52% | 12,083.33% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.88% | 0.15% | 34.07% | 1,317.31% | |
Graham Net Nets |
(2.75) | (10.17) | (9.57) | (3.10) | |
Graham Number |
0.00 | 0.00 | 0.00 | 102.73 | |
Earnings Yield |
(569.68%) | (2,665.69%) | (1,216.15%) | (377.74%) | |
Free Cash Flow Yield |
(187.10%) | (599.93%) | (670.84%) | (157.04%) | |
Revenue per Share |
0.10 | 7.24 | 0.08 | 0.04 | |
Operating CF per Share |
(2.99) | (1.74) | (9.60) | (8.60) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.99) | (1.74) | (9.60) | (8.60) | |
Cash per Share |
0.56 | 1.36 | 5.58 | 2.91 | |
Shareholders Equity per Share |
5.59 | 6.37 | 7.91 | (5.59) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.59 | 6.37 | 7.91 | (5.59) | |
Free Cash Flow |
(3.97) | (1.58) | (3.36) | (3.24) | |
Working Capital |
(17.51) | (18.24) | (18.78) | (25.27) | |
Net Current Asset Value |
(18.20) | (19.86) | (19.47) | (25.96) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.02 | 0.08 | 0.31 | 0.34 | |
Average Payables |
14.98 | 15.76 | 17.74 | 20.82 | |
Average Assets |
27.84 | 26.81 | 27.38 | 26.00 | |
Average Common Equity |
3.69 | (1.40) | (2.00) | (6.04) |
Columns are period end dates · fundamentals updated 26 Oct 2026